Dihydromyricetin is a vine-tea plant compound now studied for skin rejuvenation. The strongest skin evidence is topical: an eight-week serum study reported younger surface-skin age scores, smoother texture, and fewer wrinkles, without a placebo comparison. Oral capsules have clearer support for metabolic liver markers than for facial aging. Short-term safety looks favorable, mainly mild gut symptoms and theoretical drug-interaction caution. (Full Review)

Protocol

Primary skin-oriented approach (topical)

Twice-daily dihydromyricetin facial serum

≥8 weeks with daily sunscreen

Oral adjunct (evidence weaker for skin)

~300–1000 mg/day

Metabolic evidence; not validated for facial aging

Timing

Morning and evening topical

Oral often with meals; split dosing more common

Time to effect

Main clinical window

8 weeks

Skin-age scores, texture, wrinkles

Early skin changes

~4 weeks

Wrinkle and dermal-density shifts

Oral skin effects

Not defined

No established onset for facial outcomes

Benefits

Medium: Reduced epidermal DNA methylation age and visible signs of skin aging

Low: Preservation of collagen, elasticity, and anti-glycation skin structure; calming support of aged fibroblasts and reduced age-related cell-stress signaling; support for wound closure and keratinocyte migration

Speculative: Systemic longevity effects translating to skin from oral supplement use; dual anti-acne actions

Contraindications

Pregnancy and lactation (insufficient data)

Children (insufficient data)

Known allergy to Vitaceae plants or prior reaction to vine tea/Hovenia products

Uncontrolled severe skin barrier disease until stabilised (topical)

Critical CYP3A4/2D6 narrow-index drugs without clinician oversight (oral)

Key Interactions

CYP3A4 substrates (e.g., certain calcium channel blockers, simvastatin/lovastatin, midazolam, cyclosporine; oral)

CYP2D6 substrates (e.g., metoprolol, codeine, tamoxifen, many SSRIs; oral)

CYP2E1 substrates/inducers (e.g., ethanol, high-dose acetaminophen, isoniazid; oral)

Sedatives / GABA_A modulators (benzodiazepines, Z-drugs such as zolpidem, barbiturates, high-dose alcohol)

Other polyphenols and antioxidant stacks

Other topical actives (retinoids, acids, vitamin C, benzoyl peroxide)

Risk & Side Effects

Medium: Potential pharmacokinetic interactions via CYP inhibition

Low: Mild gastrointestinal discomfort; local skin irritation from multi-ingredient topical serums

Speculative: Sedation or altered alcohol response via GABA pathways; unknown reproductive and pediatric safety; theoretical epigenetic off-target effects from chronic DNA-methylation enzyme inhibition

Monitoring

Marker	Target	Why
Standardized facial photos	Trend over time	Track wrinkles, texture, radiance
Dermal echogenicity (HFUS) if available	Stable or increasing vs baseline	Proxy for dermal density
Skin elasticity / firmness (cutometry) if available	Stable or improving	Functional biomechanics
ALT	Often targeted ~<25–30 U/L (sex-specific lab ranges vary)	Oral dihydromyricetin liver safety / metabolic context
AST	Within lab reference; track trend	Hepatocyte stress signal
GGT	Low-normal for lab	Cholestatic/alcohol/metabolic signal
Fasting glucose or HbA1c	Glucose ~70–90 mg/dL; HbA1c ~4.8–5.3% (individualized)	Metabolic milieu for glycation
hs-CRP	Often <1.0 mg/L	Systemic inflammation

Cadence: Photos at 4 weeks, 8 weeks, then every 3–6 months; labs at ~3 months after starting oral use, then every 6–12 months if continued and stable

Qualitative Assessment

Reduced appearance of fine lines and crow’s feet under consistent lighting
Smoother makeup application / less rough texture on touch
Improved firmness or bounce on gentle pinch (subjective)
Absence of stinging, peeling, or persistent redness from the serum
No new GI upset, unusual fatigue, or medication effect changes on oral use

Dihydromyricetin for Skin Rejuvenation

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment